文献速递创伤与烧伤心脑血管急症

锁骨下与腋动脉损伤的当代管理:西部创伤协会多中心回顾

Contemporary management of subclavian and axillary artery injuries-A Western Trauma Association multicenter review.
PubMed 文献 · J Trauma Acute Care Surg · 2017-01-01
一句话结论11家西部创伤协会中心223例回顾显示:开放手术仍占61%、用于93%的>50%周径撕裂和83%血管横断,血管内修复17%多用于假性动脉瘤,住院死亡率10%、保肢率97%。

该多中心回顾纳入2004年1月1日至2014年12月31日11家西部创伤协会机构的223例锁骨下或腋动脉损伤患者,平均年龄36岁、84%为男性。研究比较开放与血管内技术的相对角色及医院结局和长期肢体存活。结果显示手术方式与损伤分级相关(p<0.001),开放手术135例(61%),血管内修复38例(17%)最常用于假性动脉瘤,杂交手术14例(6%);住院死亡率10%,移植物或支架血栓7%、感染3%,平均随访1.6±2.4年(n=150)时保肢216例(97%)。结论认为此类损伤仍需多种开放暴露与手术,尤其控制>50%血管撕裂和横断的活动性出血;血管内修复最常用于假性动脉瘤。

要点

  • 开放手术135例(61%),覆盖93%的>50%周径撕裂和83%血管横断,主要用于控制活动性出血。
  • 血管内修复38例(17%),最常用于假性动脉瘤;杂交手术14例(6%)。
  • 研究期间CT血管造影使用增加、常规血管造影减少(p=0.018),血管内较开放手术的使用未增加(p=0.248)。
  • 住院死亡率10%,移植物或支架血栓7%、感染3%。
  • 平均随访1.6±2.4年(n=150)时保肢216例(97%)。

适用人群与场景

  • 2004年1月1日至2014年12月31日在11家西部创伤协会机构就诊的锁骨下或腋动脉损伤患者,共223例,平均年龄36岁,84%为男性。

处置流程与药物剂量

  • 开放手术用于135例(61%),包括93%的>50%周径撕裂和83%血管横断。
  • 血管内修复用于38例(17%),最常用于假性动脉瘤。
  • 杂交手术用于14例(6%)。

研究设计与关键结果

  • 多中心回顾性研究,纳入223例锁骨下或腋动脉损伤患者(锁骨下120例、腋动脉119例),平均年龄36岁,84%为男性。
  • 手术方式与损伤分级相关(p<0.001);开放手术135例(61%),血管内修复38例(17%),杂交手术14例(6%)。
  • 研究期间CT血管造影增加、常规血管造影减少(p=0.018);血管内较开放手术的使用未增加(p=0.248)。
  • 住院死亡率10%;移植物或支架血栓7%,移植物或支架感染3%。
  • 平均随访1.6±2.4年(n=150),保肢216例(97%)。

证据类型、等级与局限

  • 证据类型:多中心回顾性研究;证据等级:预后/流行病学,level IV。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于>50%周径撕裂和血管横断的活动性出血,开放手术仍是主要控制手段(93%和83%接受开放手术)。
  • 血管内修复在本队列中最常用于假性动脉瘤。
  • 作者认为,锁骨下与腋动脉损伤的管理仍需要多种开放暴露和手术,尤其是控制>50%血管撕裂和横断的活动性出血。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Subclavian and axillary artery injuries are uncommon. In addition to many open vascular repairs, endovascular techniques are used for definitive repair or vascular control of these anatomically challenging injuries. The aim of this study was to determine the relative roles of endovascular and open techniques in the management of subclavian and axillary artery injuries comparing hospital outcomes, and long-term limb viability.

METHODS: A multicenter, retrospective review of patients with subclavian or axillary artery injuries from January 1, 2004, to December 31, 2014, was completed at 11 participating Western Trauma Association institutions. Statistical analysis included χ, t-tests, and Cochran-Armitage trend tests. A p value less than 0.05 was significant.

RESULTS: Two hundred twenty-three patients were included; mean age was 36 years, 84% were men. An increase in computed tomography angiography and decrease in conventional angiography was observed over time (p = 0.018). There were 120 subclavian and 119 axillary artery injuries. Procedure type was associated with injury grade (p < 0.001). Open operations were performed in 135 (61%) patients, including 93% of greater than 50% circumference lacerations and 83% of vessel transections. Endovascular repairs were performed in 38 (17%) patients; most frequently for pseudoaneurysms. Fourteen (6%) patients underwent a hybrid procedure. Use of endovascular versus open procedures did not increase over the duration of the study (p = 0.248). In-hospital mortality rate was 10%. Graft or stent thrombosis occurred in 7% and graft or stent infection occurred in 3% of patients. Mean follow-up was 1.6 ± 2.4 years (n = 150). Limb salvage was achieved in 216 (97%) patients.

CONCLUSION: The management of subclavian and axillary artery injuries still requires a wide variety of open exposures and procedures, especially for the control of active hemorrhage from more than 50% vessel lacerations and transections. Endovascular repairs were used most often for pseudoaneurysms. Low early complication rates and limb salvage rates of 97% were observed after open and endovascular repairs.

LEVEL OF EVIDENCE: Prognostic/epidemiologic, level IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Waller CJ, Cogbill TH, Kallies KJ, et al. Contemporary management of subclavian and axillary artery injuries-A Western Trauma Association multicenter review. J Trauma Acute Care Surg. 2017. PMID: 28715360. doi:10.1097/TA.0000000000001645

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。